EPO and heart failure: This triggers moderate hepatic and renal EPO production and corresponding changes in hemoglobin levels indicate SGLT2is’ efficacy in lowering the risk of cardiovascular death and heart failure hospitalizations.139,540,541 Also, using the HIF-2α inhibitor PT2399 countered the effects of dapagliflozin on cardiac fibrosis and inflammation in arrhythmogenic cardiomyopathy.542 In addition, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are new drugs for high cholesterol and heart problems.